What Radiesse does

Radiesse is a proprietary injectable biostimulator brand marketed by Merz North America, Inc., a wholly-owned subsidiary of Merz Pharma GmbH & Co. KGaA headquartered in Franksville, Wisconsin. The product uses calcium hydroxylapatite (CaHA) microspheres suspended in a carboxymethylcellulose gel carrier to activate fibroblasts through a non-inflammatory regenerative pathway, stimulating production of collagen, elastin, and proteoglycans rather than relying on pronounced inflammation. RADIESSE® and RADIESSE® (+) (the latter containing 0.3% lidocaine for patient comfort) are FDA-approved prescription-only medical devices indicated for smoothing moderate-to-severe facial wrinkles and folds, restoring volume in the dorsum of the hands, and—when diluted 1:2 with sterile saline—correcting décolleté wrinkles in patients 22 and older, while RADIESSE (+) is additionally approved for deep injection to improve jawline contour in adults over 21.

The brand is distributed exclusively through a network of trained and certified healthcare providers (aesthetic physicians, dermatologists, plastic surgeons, and nurse injectors), with indication-specific FDA-mandated training required for jawline and décolleté procedures. Provider enablement is delivered through the Merz Aesthetics Exchange (MAX) training and practice-development platform, and the consumer-facing motion is supported by an Instagram and Facebook presence, a 'Find a Provider' locator tool, the Xperience+ loyalty rewards program, and co-marketing partnerships such as the Sports Illustrated Swimsuit collaboration. Recent positioning has specifically targeted patients experiencing facial volume depletion following rapid weight loss, including users of GLP-1 medications.

Revenue is generated through unit-priced sales of syringes to the certified provider network; treatment-level pricing is set by individual providers and is not publicly disclosed. The Radiesse brand operates within the broader Merz Aesthetics portfolio inside Merz North America, Inc., and no brand-level revenue, unit, or financial disclosures are publicly available. The operating entity reports 501–1,000 employees across Merz North America, indicating a substantial but undisclosed revenue base distributed across multiple Merz aesthetic brands.

Name

Radiesse

Legal name

Merz North America, Inc.

Website

https://radiesse.com

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Radiesse is Merz North America's prescription injectable biostimulator brand, distributing calcium hydroxylapatite (CaHA)-based fillers through certified aesthetic healthcare providers for facial wrinkles, hand volume, jawline contouring, and décolleté rejuvenation, recently positioned for GLP-1 weight-loss patients.

Ownership category

akta.pro rank

Product category

Injectable Dermal Fillers and Biostimulators

NAICS

Toilet Preparation Manufacturing (325620)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Professional Skincare & Facial Treatments (CRABALAF)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Injectable dermal fillers
• Calcium hydroxylapatite biostimulators
• Collagen biostimulation treatments
• Facial rejuvenation products
• Medical aesthetic injectables

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. RADIESSE Injectable Product Sales: RADIESSE and RADIESSE (+) are prescription-only medical devices sold to licensed healthcare providers (aesthetic physicians, dermatologists, plastic surgeons, nurse injectors) who then administer treatments to patients. Revenue is generated through product sales to the provider network, with each treatment involving one or more syringes depending on treatment area and patient needs.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Radiesse manufactures and sells prescription-only injectable biostimulator products (RADIESSE® and RADIESSE® (+)) containing calcium hydroxylapatite (CaHA) microspheres that are administered by licensed healthcare providers to smooth moderate to severe facial wrinkles and folds, restore volume to the dorsum of the hands, contour the jawline, and — using a 1:2 hyperdiluted preparation — correct décolleté wrinkles. The products are sold B2B through a network of certified aesthetic physicians, dermatologists, plastic surgeons, and nurse injectors, with treatment outcomes supported by clinical studies showing results lasting up to two years.

Product overview

Radiesse is a portfolio of injectable biostimulator products by Merz North America, Inc. The core products are RADIESSE® and RADIESSE® (+), both containing calcium hydroxylapatite (CaHA) microspheres that activate the skin's regenerative pathway to boost collagen, elastin, and proteoglycans. RADIESSE® serves as the foundational biostimulator for facial wrinkles and hand volume correction, while RADIESSE® (+) includes lidocaine for jawline contouring. The hyperdiluted 1:2 protocol extends treatment to the décolleté area. The portfolio is supported by the Xperience+™ loyalty rewards program and the Merz Aesthetics Exchange (MAX) training platform. Results can last up to 2 years.

Differentiator

Problem solved

Functional benefit

Products and services

• RADIESSE® Injectable biostimulator containing calcium hydroxylapatite (CaHA) microspheres for smoothing moderate to severe facial wrinkles and folds (such as nasolabial folds), correcting volume loss in the back of the hands, and when diluted 1:2 with saline, treating décolleté wrinkles. Approved for adults aged 22 and older and sold to certified healthcare providers.
• RADIESSE® (+) RADIESSE formulation with lidocaine hydrochloride (0.3%) for improved patient comfort during injection. FDA-approved for smoothing moderate to severe facial wrinkles and folds, as well as for deep injection to improve moderate to severe loss of jawline contour in adults over the age of 21.
• Hyperdiluted RADIESSE (1:2 Protocol) Specialized preparation of RADIESSE mixed 1:2 with 0.9% sterile saline solution, specifically approved for décolleté (chest) wrinkle correction. The hyperdilution lowers viscosity, allowing coverage of the larger décolleté surface area with biostimulatory microspheres.

Quantifiable outcome

• 23x more collagen versus placebo (6-month human tissue study)
• +9 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Sports Illustrated SwimsuitcoreGTM or Marketing PartnerRADIESSE partnered with Sports Illustrated Swimsuit to present 'Love Letters From Our Future Self,' a video exploring themes of self-love, confidence, and investing in personal well-being. This co-promotional campaign leverages the iconic brand's association with body confidence and beauty to position RADIESSE as a premium aesthetic treatment.

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Galderma: Global dermatology and aesthetics company whose Sculptra (PLLA) is the closest biostimulator competitor to RADIESSE's CaHA technology, and which also markets the Restylane hyaluronic acid filler portfolio. Direct head-to-head competitor across the biostimulator and dermal filler categories served by similar provider networks.
• Sinclair Pharma (Galderma-owned Ellansé): Markets Ellansé, a polycaprolactone (PCL)-based biostimulator that competes directly with RADIESSE on collagen-stimulator positioning and duration claims. Same provider channels, same indication categories, and head-to-head mechanism of action (PCL vs CaHA).
• Teoxane Laboratories: Swiss aesthetics company marketing a portfolio of hyaluronic acid dermal fillers (RHA-equivalent technology) for facial rejuvenation. Directly comparable target market, indication overlap, and provider-channel distribution.

Broad incumbents

• AbbVie Allergan Aesthetics: Markets the Juvéderm hyaluronic acid filler family and Botox, the dominant aesthetics franchise globally. Comparable provider network, distribution model, and aesthetic indications; competes with RADIESSE for both injector preference and patient share-of-wallet, though it spans a much broader aesthetics portfolio.
• Merz Pharma GmbH & Co. KGaA: Parent company of Merz North America (RADIESSE's owner) and operator of sister aesthetics brands including Belotero (HA filler), Xeomin (neurotoxin), and Ultherapy. Comparable aesthetics portfolio and provider network, but a broader, multi-brand incumbent.

Emerging players

• Evolus: U.S. aesthetics company marketing Jeuveau, a neurotoxin competing in the same provider channels as RADIESSE. Comparable customer base (aesthetic practices) and provider-channel economics, though Evolus is focused on neurotoxins rather than biostimulators/fillers.
• Revance Therapeutics: Markets Daxxify (long-duration neurotoxin) and the RHA Collection of resilient hyaluronic acid fillers. Operates in the same provider-driven aesthetic channel with comparable patient indications (facial wrinkles and folds), positioning as an emerging multi-modality competitor.
• Prollenium Medical Technologies: Canadian manufacturer of the Revanesse line of hyaluronic acid dermal fillers, distributed through the same medical-aesthetics channel in North America. Emerging challenger competing for provider preference and price-sensitive patient segments.
• Hugel America: Subsidiary of Korea's Hugel Inc., marketing Botulax/Letybo neurotoxins and a dermal filler portfolio in the U.S. aesthetic channel. Comparable end customer (aesthetic providers) and overlapping facial-rejuvenation indications, with growing U.S. share.
• BioScience GmbH (Lanluma): German aesthetics company marketing Lanluma, a PLLA-based injectable biostimulator for body and facial indications. Directly comparable biostimulator positioning and overlapping provider/distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Radiesse
• Instagraminstagram.com/radiesse

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radiesse